Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
By Elana Gotkine HealthDay Reporter
MONDAY, April 21, 2025 -- Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to a review published in the May issue of The Lancet Psychiatry.
Luis C. Farhat, Ph.D., from the Universidade de São Paulo in Brazil, and colleagues compared the effects of pharmacological treatments for ADHD on hemodynamic signs and electrocardiographic parameters in children, adolescents, and adults. Published and unpublished randomized controlled trials (RCTs) comparing amphetamines, atomoxetine, bupropion, clonidine, guanfacine, lisdexamfetamine, methylphenidate, modafinil, or viloxazine -- either against each other or against placebo -- were identified; 101 RCTs with short-term follow-up were included, encompassing 22,257 participants.
The researchers found that in children and adolescents, adults, or both, amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine led to increases in hemodynamic signs. Among children and adolescents, the mean increase against placebo varied from 1.07 mm Hg with atomoxetine to 1.81 mm Hg with methylphenidate for systolic blood pressure; from 1.93 mm Hg with amphetamines to 2.42 mm Hg with methylphenidate for diastolic blood pressure; and from 2.79 beats per minute (bpm) with viloxazine to 5.58 bpm with atomoxetine for pulse. Among adults, the mean increase against placebo ranged from 1.66 mm Hg with methylphenidate to 2.3 mm Hg with amphetamines for systolic blood pressure; from 1.6 mm Hg with methylphenidate to 3.07 mm Hg with lisdexamfetamine for diastolic blood pressure; and from 4.37 bpm with methylphenidate to 5.8 bpm with viloxazine for pulse. In children and adolescents, and in adults, guanfacine was associated with decrements in hemodynamic signs.
"Our findings confirmed that amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine may lead to short-term increments in heart rate, blood pressure, or both in children and adolescents, adults, or both age groups," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than...
Intensive BP Reduction Effective for Lowering All-Cause Dementia Risk
TUESDAY, April 29, 2025 -- An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and...
Early Pregnancy BP Trajectories Linked to New-Onset HTN Years Later
THURSDAY, April 17, 2025 -- Early pregnancy blood pressure (BP) trajectories are associated with new-onset hypertension up to 14 years later, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.